- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04042025
Estudio de seguimiento a largo plazo de pacientes que reciben onasemnogén Abeparvovec-xioi
Un estudio de seguimiento a largo plazo de pacientes en los ensayos clínicos para la atrofia muscular espinal que recibieron AVXS-101
This is a long-term follow-up safety and efficacy study of participants in clinical trials for spinal muscular atrophy (SMA) who were treated with onasemnogene abeparvovec-xioi. Participants will roll over from their respective previous (parent) study into this long-term study for continuous monitoring of safety as well as monitoring of continued efficacy and durability of response to onasemnogene abeparvovec-xioi treatment.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2145
- Sydney Children's Hospital
-
-
-
-
-
Ghent, Bélgica, 9000
- Universitair Ziekenhuis Gent
-
-
Liège
-
Liège, Liège, Bélgica, B-4000
- Centre de Référence des Maladies Neuromusculaires
-
-
-
-
Ontario
-
Ottawa, Ontario, Canadá, K1H8L1
- Children's Hospital of Eastern Ontario Research Institute
-
-
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Stanford University Medical Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Children's Hospital Colorado
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Ann Robert H. Lurie Children's Hospital of Chicago
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- John Hopkins Hospital - David M. Rubenstein Child Health Building
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02115
- Boston Children's Hospital
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Spectrum Health Hospitals Helen DeVos Children's Hospital
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington Unviersity School of Medicine in Saint Louis
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Columbia University Medical Center
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27713
- Duke University
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Children's Hospital of Philadelphia
-
Strasburg, Pennsylvania, Estados Unidos, 17579
- Clinic for Special Children
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235
- Children's Health Specialty Center Dallas Campus
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- University of Utah Health
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos, 23507
- Children's Hospital of The King's Daughters
-
Richmond, Virginia, Estados Unidos, 23298
- Virginia Commonwealth University
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin, Madison
-
-
-
-
-
Paris, Francia, 75012
- Hôpital Armand Trousseau
-
-
-
-
-
Genova, Italia, 16147
- Instituto Gianninia Gaslini
-
Milan, Italia, 20133
- Istituto Neurologico di Ricerca
-
Milan, Italia, 20122
- Universita Degli Studi Di Milano
-
-
Roma
-
Roma, Roma, Italia, 00168
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Tokyo, Japón, 162-8666
- Tokyo Women's Medical University Hospital
-
-
-
-
-
Newcastle upon Tyne, Reino Unido, NE1 4LP
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust
-
-
London
-
London, London, Reino Unido, WC1N 3JH
- Great Ormond Street Hospital for Children NHS Foundation Trust
-
-
-
-
-
Taipei, Taiwán, 10048
- National Taiwan University Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Any participant with SMA who received onasemnogene abeparvovec-xioi gene replacement therapy in a Novartis Gene Therapies-sponsored clinical study
- Participant/parent/legal guardian willing and able to complete the informed consent process and comply with study procedures and visit schedule
Exclusion Criteria:
- Parent/legal guardian unable or unwilling to participate in the long-term follow-up safety study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec-xioi
Participants received treatment with IV onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi or received treatment with IT onasemnogene abeparvovec-xioi in an onasemnogene. |
Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cambio desde la línea de base en las medidas de altura
Periodo de tiempo: Hasta 5 años
|
Hasta 5 años
|
|
|
Cambio desde la línea de base en las mediciones de peso
Periodo de tiempo: Hasta 5 años
|
Hasta 5 años
|
|
|
Número de participantes con medicamentos concomitantes en general y por tipo de medicamentos
Periodo de tiempo: Hasta 5 años
|
Hasta 5 años
|
|
|
Número de participantes con otras terapias para la AME en general y por tipo de medicamentos
Periodo de tiempo: Año 6 a Año 15
|
Año 6 a Año 15
|
|
|
Number of Participants Who Reach Developmental Milestones
Periodo de tiempo: Up to 5 years
|
Assessed via the developmental milestone checklist, formed of 10 yes/no questions. The developmental milestones are: head control, sitting with support, sitting without support, sitting without support for 30 seconds, hands-and-knees crawling, pulls to stand, standing with assistance, walking with assistance, standing alone and walking alone. |
Up to 5 years
|
|
Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score
Periodo de tiempo: Up to 5 years
|
The HFMSE was devised for use in children with SMA to give objective information on motor ability and clinical progression. The HFMSE is formed of 33 assessments rated from 0 (unable to perform functional task) to 2 (able to perform functional task unassisted). Higher scores on the total scale of 0-66 indicates higher levels of motor ability. |
Up to 5 years
|
|
Number of Participants Who Experience a Clinically Significant Change From Baseline in Pulmonary Assessment Results and Require Ventilatory Support
Periodo de tiempo: Up to 15 years
|
Participants will receive pulmonary assessments by a pulmonologist or appropriate clinician. Respiratory device data will be reviewed for participants receiving non-invasive ventilatory support. |
Up to 15 years
|
|
Number of Participants Who Experience Swallowing Dysfunction and Require Nutritional Support
Periodo de tiempo: Up to 5 years
|
Assessed via the swallowing function questionnaire, formed of 4 yes/ no questions and 1 body weight question. |
Up to 5 years
|
|
Number of Participants Who Experience a Clinically Significant Change from Baseline in Physical Examination Findings
Periodo de tiempo: Up to 5 years
|
The physical examination includes review of the following systems: head, ears, eyes, nose and throat, lungs/thorax, cardiovascular, abdomen, musculoskeletal, neurologic, dermatologic, lymphatic, and genitourinary. In addition, visual inspection of the spine, back, shoulders, and hips looking for spinal curvature and asymmetry will be carried out. Joints will be assessed for loss of mobility and contractures. |
Up to 5 years
|
|
Number of Participants Who Experience a Clinically Significant Change From Baseline in Vital Signs Measurements
Periodo de tiempo: Up to 5 years
|
Vital sign measurements will include blood pressure, respiratory rate, pulse, axillary temperature, and pulse oximetry. |
Up to 5 years
|
|
Number of Participants Who Experience a Clinically Significant Change From Baseline in Clinical Laboratory Assessments
Periodo de tiempo: Up to 5 years
|
Blood samples will be collected for hematology (including complete blood cell count) and chemistry. |
Up to 5 years
|
|
Number of Participants Who Experience a Clinically Significant Change From Baseline in Cardiac Assessments
Periodo de tiempo: Up to 5 years
|
Cardiac assessments will include a 12-lead electrocardiogram, transthoracic echocardiogram and Troponin-I. |
Up to 5 years
|
|
Number of Participants Who Experience a Clinically Significant Change From Baseline in Observational Phase Questionnaire Results
Periodo de tiempo: Year 6 to Year 15
|
The observational phase questionnaire includes 7 yes/no questions. Observation categories include: adverse events, hospitalizations, concomitant medications, ventilatory support and feeding support. |
Year 6 to Year 15
|
|
Number of Participants Who Experience at Least One Serious Adverse Event (SAE)
Periodo de tiempo: Up to 15 years
|
An SAE is defined as any adverse event (appearance of [or worsening of any pre existing]) undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria:
|
Up to 15 years
|
|
Number of Participants Who Experience at Least One Adverse Event of Special Interest (AESI)
Periodo de tiempo: Up to 15 years
|
An AESI is defined as an AE occurring during any study phase that fulfills one of the following criteria:
|
Up to 15 years
|
|
Change From Baseline in Bayley Scales of Infant and Toddler Development
Periodo de tiempo: Up to 42 months, 15 days of age
|
Third Edition (Bayley-III) to be performed in all patients up to 42 months, 15 days of age. |
Up to 42 months, 15 days of age
|
|
Change From Baseline in Revised Upper Limb Module (RULM) Score
Periodo de tiempo: Up to 5 years
|
RULM score is based on a scale from 0 to 37 where lower scores reflect poorer upper limb functional ability. |
Up to 5 years
|
|
Change From Baseline in Cogstate Computerized Cognitive Battery Performed in Age 48 Months and Older
Periodo de tiempo: Up to 5 years
|
The Cogstate Computerized Cognitive Battery consists of the Identification Test (scored 0 (best) to 1.5708 (worst)), the International Shopping List Test (scored 0 (worst) to 999 (best)), the International Shopping List Test-Delayed Recall (scored 0 (worst) to 999 (best)), the One Card Learning Test (scored 0 (worst) to 1.5708 (best)), and the One Back Test (scored 0 (worst) to 1.5708 (best)). |
Up to 5 years
|
|
Change From Baseline in Clinical Evaluation of Language Fundamentals Fifth Edition (CELF-5) Performed in All Participants 5 to 21 Years of Age
Periodo de tiempo: Up to 5 years
|
The CELF-5 Following Directions and Sentence Repetition subtests use scoring that varies based on age, but will be administered to participants 5-21 years of age. The Following Directions subtest will be scored from 0-33 with higher score being more advanced and the Recalling Sentences subtest will be scored from 0-78 with higher score being more advanced. |
Up to 5 years
|
|
Change From Baseline in Assessment of Caregiver Experience With Neuromuscular Disease (ACEND)
Periodo de tiempo: Up to 5 years
|
ACEND score is based on a scale from 1 to 41 where higher scores represent a better caregiver experience |
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Sitra Tauscher-Wisniewski, MD, Novartis Gene Therapies, Inc.
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Neuromusculares
- Enfermedades Genéticas Congénitas
- Enfermedades neurodegenerativas
- Trastornos Heredodegenerativos, Sistema Nervioso
- Enfermedades de la médula espinal
- Enfermedad de la neuronas motoras
- Atrofia Muscular Espinal
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Atrofias musculares espinales de la infancia
- Zolgensma
Otros números de identificación del estudio
- AVXS-101-LT-002
- 2019-002611-26 (Número EudraCT)
- 205305 (Otro identificador: JapicCTI)
- COAV101A12103 (Otro identificador: Novartis Pharmaceuticals)
- 2019 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .